Skip to main content

Advertisement

Table 1 Factor contents of commercially available PCCs

From: Role of prothrombin complex concentrate in perioperative coagulation therapy

  FII IU/ml FVII IU/ml FIX IU/ml FX IU/ml PC IU/ml PS IU/ml Hepari U/ml
4-factor PCC
 Beriplex/Kcentra (CSL Behring, Germany) 20–48 10–25 20–31 22–60 15–45 13–26 0.4–2
 Octaplex (Octapharma, Austria) 11–38 9–24 25 18–30 7–31 7–32 <15
 Prothromplex Total (Baxter, Austria) 24–45 25 30 30 >20 N.Q. <15
 PPSB-HT (Nichiyaku, Japan) 20 20 20 20 15–45 N.Q. 5
 Cofact (Sanquin, Netherlands) 14–35 7–20 25 14–35 11–39 1–8 None
3-factor PCC
 Bebulin (Baxter, USA) 30 3–5 25 35 N.Q. N.Q. 3.75
 Profilnine (Octapharma, Austria) 37 3 25 16 N.Q. N.Q. None
Activated PCC
 FEIBA (Baxter, USA) + + (FVIIa) + + (FXa) N.Q. N.Q. None
  1. Other PCC products are also available in different countries. PCCs containing heparin are contraindicated in patients with heparin-induced thrombocytopenia. The potency of each PCC vial is according to the FIX activity except for FEIBA, which is dosed according to FVIII bypassing activity unit. Data are shown based on the prescribing information for each product; actual factor contents may vary for each vial.
  2. PC/PS protein C/protein S, N.Q. not quantified.